Transcode TherapeuticsRNAZ
13F holders, Q3 2025 (September 30)8holders −1
3new positions
4sold out
$10.74avg. 13F price*
At the end of Q3 2025, 8 institutions reported holding Transcode Therapeutics Inc. (RNAZ) in their 13F filings, down 1 from Q2 2025. 3 opened new positions and 4 sold out. The largest holders were DRW Securities, LLC ($126K), Citigroup Inc. ($17K) and Federation des caisses Desjardins du Quebec ($10K).
- Company
- Transcode Therapeutics Inc.
- CUSIP
- 89357L501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $153K |
| Exits | 4 | $234K |
All 13F filers, Q2 2025 → Q3 2025: 14,263 shares bought and 30,219 shares sold, net −15,956 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| DRW Securities, LLC | 0.01% | New | 11,702 | $126K |
| Citigroup Inc. | 0.00% | New | 1,586 | $17K |
| Federation des caisses Desjardins du Quebec | 0.00% | New | 975 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -64.7% | 142 | $2K |
| SBI Securities Co., Ltd. | 0.00% | No change | 10 | $108 |
| Bank of America Corp. | 0.00% | No change | 8 | $86 |
| Osaic Holdings, Inc. | 0.00% | No change | 3 | $29 |
| Royal Bank of Canada | 0.00% | No change | 8 | $0 |
"% of holder's portfolio" is RNAZ's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.